Definium Therapeutics’ Phase 3 Anxiety Trials Show Improvements of 5.4 and 5.1 Points
Key Facts
Definium Therapeutics said its two Phase 3 studies, Voyage and Panorama, of DT120 ODT for generalized anxiety disorder met the primary endpoint and all key secondary endpoints. At week 12, the adjusted improvement versus placebo was 5.4 points in Voyage and 5.1 points in Panorama on the HAM-A scale. The scale measures anxiety symptoms, while the figures reflect the difference recorded between treatment and placebo at the specified measurement point. The company described the improvement as statistically significant and clinically meaningful. The results are central to the drug’s development path, as the company aims to advance it to a regulatory filing.
The company reported a net loss of $51.0 million in the third quarter of 2026, compared with a loss of $67.3 million in the same quarter of 2025. It attributed part of the improvement to fair-value gains on warrants and higher interest income. The comparison shows a narrower loss between the two periods, with the company attributing part of the change to those two financial factors. The quarterly results come alongside the development of its clinical programs. The company said research and development and administrative expenses reflect program expansion and commercial preparation, but detailed figures for those expenses are not included in the available information.
In the DT120 ODT depression program, the Phase 3 Emerge study showed an adjusted improvement versus placebo of 8.1 points on the MADRS scale at week six. The company also announced that the treatment had received Breakthrough Therapy designation from the U.S. Food and Drug Administration for major depressive disorder. The result adds another therapeutic path to the DT120 program, alongside the two generalized anxiety disorder studies. The measurement timing differs between the programs: week six in Emerge and week 12 in Voyage and Panorama. The expected filing in the first half of 2027 remains tied to DT120 ODT, according to the company.
The company expects to file a New Drug Application for DT120 ODT in the first half of 2027, after a planned meeting with the Food and Drug Administration to discuss the application. The timeline sets out the next regulatory milestone the company has announced for the drug. In its post-traumatic stress disorder program, the company expects to begin the Phase 3 Haven study during 2027, with about 200 participants. The planned study start follows the announced results in anxiety and depression, as part of the DT120 ODT development program across multiple indications. The available information does not specify a more precise start date for Haven during 2027.
DFTX shares closed at $32.08 on November 13, 2026, according to EL7 data. The closing price provides a reference for the stock in that session, following the company’s announcement of results and expectations for the DT120 ODT program. The available EL7 data do not include the stock’s daily trading range on that date. The information also does not provide a documented figure for the share-price move in response to the announcement. Market context is therefore limited to the closing price recorded on November 13.